ArsenalBio

Vision Fund investment portfolio company ArsenalBio's logo

ArsenalBio is fighting cancer by developing next generation T cell therapies.

Leadership
Ken Drazan
Fund
SVF2
Status
Private
Website
Sector
Health Tech
Region
Americas

Insights
SoftBank Vision Fund Asset
Q&A
Ken Drazan: Building an LLM that speaks the language of the immune system

How ArsenalBio is targeting cancers and accelerating the speed of biomedical research

SoftBank Vision Fund Asset
Roundup
Data and machine learning are creating a golden age of drug discovery

The biotech sector is poised to reap the benefits of the AI revolution, with lifesaving effects